Antares Pharma Stock Price, News & Analysis (NASDAQ:ATRS)

$2.01 0.08 (4.15 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$2.01
Today's Range$1.92 - $2.06
52-Week Range$1.58 - $4.09
Volume2.14 million shs
Average Volume879,198 shs
Market Capitalization$302.38 million
P/E RatioN/A
Dividend YieldN/A
Beta0.26

About Antares Pharma (NASDAQ:ATRS)

Antares Pharma logoAntares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company's subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.

Receive ATRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:ATRS
CUSIP03664210
Phone609-359-3020

Debt

Debt-to-Equity Ratio0.69%
Current Ratio3.34%
Quick Ratio2.89%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$52.22 million
Price / Sales6.03
Cash FlowN/A
Price / CashN/A
Book Value$0.29 per share
Price / Book6.93

Profitability

Trailing EPS($0.11)
Net Income$-24,330,000.00
Net Margins-32.06%
Return on Equity-43.05%
Return on Assets-24.14%

Miscellaneous

Employees110
Outstanding Shares156,670,000

Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

How were Antares Pharma's earnings last quarter?

Antares Pharma, Inc. (NASDAQ:ATRS) issued its quarterly earnings results on Tuesday, November, 7th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.03). The specialty pharmaceutical company had revenue of $15.10 million for the quarter, compared to analyst estimates of $14.01 million. Antares Pharma had a negative return on equity of 43.05% and a negative net margin of 32.06%. The firm's revenue was up 11.9% on a year-over-year basis. View Antares Pharma's Earnings History.

Where is Antares Pharma's stock going? Where will Antares Pharma's stock price be in 2017?

4 Wall Street analysts have issued 1 year price targets for Antares Pharma's stock. Their predictions range from $3.00 to $5.00. On average, they expect Antares Pharma's share price to reach $3.95 in the next year. View Analyst Ratings for Antares Pharma.

Who are some of Antares Pharma's key competitors?

Who are Antares Pharma's key executives?

Antares Pharma's management team includes the folowing people:

  • Leonard S. Jacob M.D., Ph.D., Independent Chairman of the Board (Age 68)
  • Robert F. Apple CPA, President, Chief Executive Officer, Director (Age 51)
  • Fred M. Powell CPA, Chief Financial Officer, Senior Vice President, Principal Financial Officer and Principal Accounting Officer (Age 56)
  • Peter J. Graham, Senior Vice President, General Counsel, Human Resources, Chief Compliance Officer (Age 50)
  • Thomas J. Garrity, Independent Director (Age 68)
  • Jacques Gonella Ph.D., Independent Director (Age 75)
  • Anton G. Gueth, Independent Director (Age 60)
  • Robert P. Roche Jr., Independent Director (Age 61)
  • Marvin S. Samson, Independent Director (Age 75)

Who owns Antares Pharma stock?

Antares Pharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (2.78%), Wells Fargo & Company MN (0.85%), California Public Employees Retirement System (0.62%), Schwab Charles Investment Management Inc. (0.36%), Perkins Capital Management Inc. (0.23%) and Rubric Capital Management LP (0.21%). Company insiders that own Antares Pharma stock include Fred M Powell, James E Fickenscher, Leonard S Jacob, Peter J Graham, Robert F Apple and Thomas J Garrity. View Institutional Ownership Trends for Antares Pharma.

Who sold Antares Pharma stock? Who is selling Antares Pharma stock?

Antares Pharma's stock was sold by a variety of institutional investors in the last quarter, including Rubric Capital Management LP and Thompson Davis & CO. Inc.. Company insiders that have sold Antares Pharma company stock in the last year include Leonard S Jacob, Robert F Apple and Thomas J Garrity. View Insider Buying and Selling for Antares Pharma.

Who bought Antares Pharma stock? Who is buying Antares Pharma stock?

Antares Pharma's stock was purchased by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., Wells Fargo & Company MN, Perceptive Advisors LLC, Raymond James Financial Services Advisors Inc., California Public Employees Retirement System, Capital Advantage Inc., First Eagle Investment Management LLC and State Board of Administration of Florida Retirement System. Company insiders that have bought Antares Pharma stock in the last two years include Fred M Powell, James E Fickenscher, Leonard S Jacob, Peter J Graham and Robert F Apple. View Insider Buying and Selling for Antares Pharma.

How do I buy Antares Pharma stock?

Shares of Antares Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Antares Pharma's stock price today?

One share of Antares Pharma stock can currently be purchased for approximately $2.01.

How big of a company is Antares Pharma?

Antares Pharma has a market capitalization of $302.38 million and generates $52.22 million in revenue each year. The specialty pharmaceutical company earns $-24,330,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. Antares Pharma employs 110 workers across the globe.

How can I contact Antares Pharma?

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]respharma.com.


MarketBeat Community Rating for Antares Pharma (ATRS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  135 (Vote Outperform)
Underperform Votes:  94 (Vote Underperform)
Total Votes:  229
MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Antares Pharma (NASDAQ:ATRS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.253.253.203.33
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $3.95$3.95$4.26$3.10
Price Target Upside: 138.67% upside138.67% upside40.13% upside12.32% upside

Antares Pharma (NASDAQ:ATRS) Consensus Price Target History

Price Target History for Antares Pharma (NASDAQ:ATRS)

Antares Pharma (NASDAQ:ATRS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/8/2017HC WainwrightReiterated RatingBuy$3.50N/AView Rating Details
10/23/2017Piper Jaffray CompaniesSet Price TargetBuy$3.00N/AView Rating Details
6/23/2017Chardan CapitalInitiated CoverageBuy$5.00HighView Rating Details
4/20/2017Raymond James FinancialInitiated CoverageStrong-Buy$4.30LowView Rating Details
5/10/2016Jefferies GroupReiterated RatingBuy$3.00N/AView Rating Details
(Data available from 12/16/2015 forward)

Earnings

Antares Pharma (NASDAQ:ATRS) Earnings History and Estimates Chart

Earnings by Quarter for Antares Pharma (NASDAQ:ATRS)

Antares Pharma (NASDAQ ATRS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.03)($0.03)$14.01 million$15.10 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.03)($0.02)$12.99 million$13.42 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.04)($0.03)$12.10 million$12.01 millionViewListenView Earnings Details
3/14/2017Q4 2016($0.04)($0.03)$12.77 million$14.20 millionViewN/AView Earnings Details
11/9/2016Q316($0.03)($0.04)$11.15 million$13.50 millionViewListenView Earnings Details
8/9/2016Q216($0.04)($0.04)$11.00 million$12.20 millionViewN/AView Earnings Details
5/9/2016Q1($0.03)($0.05)$11.10 million$12.30 millionViewN/AView Earnings Details
3/8/2016Q415($0.03)($0.04)$12.53 million$11.80 millionViewN/AView Earnings Details
11/5/2015Q3 15($0.03)($0.04)$10.14 million$11.09 millionViewN/AView Earnings Details
8/10/2015Q215($0.03)($0.01)$10.93 million$14.40 millionViewListenView Earnings Details
5/11/2015Q115($0.04)($0.05)$9.22 million$8.30 millionViewListenView Earnings Details
3/12/2015Q414($0.05)($0.08)$8.50 million$8.40 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.07)($0.05)$6.92 million$6.57 millionViewN/AView Earnings Details
8/7/2014Q214($0.08)($0.07)$6.43 million$6.30 millionViewN/AView Earnings Details
5/9/2014Q114($0.04)($0.07)$6.17 million$5.20 millionViewN/AView Earnings Details
3/13/2014Q413($0.05)($0.04)$6.20 million$4.70 millionViewN/AView Earnings Details
11/6/2013Q313($0.04)($0.05)$5.86 million$5.50 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.03)($0.04)$5.82 million$5.84 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.03)($0.03)$5.12 million$4.50 millionViewN/AView Earnings Details
3/13/2013Q4 2012($0.03)($0.04)$5.36 million$5.50 millionViewN/AView Earnings Details
11/7/2012Q312($0.03)($0.03)$5.62 million$5.68 millionViewN/AView Earnings Details
8/8/2012($0.03)($0.03)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Antares Pharma (NASDAQ:ATRS) Earnings Estimates

2017 EPS Consensus Estimate: ($0.14)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.04)($0.04)($0.04)
Q2 20172($0.03)($0.03)($0.03)
Q3 20172($0.04)($0.03)($0.04)
Q4 20172($0.03)($0.03)($0.03)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Antares Pharma (NASDAQ:ATRS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Antares Pharma (NASDAQ ATRS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.60%
Institutional Ownership Percentage: 34.65%
Insider Trades by Quarter for Antares Pharma (NASDAQ:ATRS)
Institutional Ownership by Quarter for Antares Pharma (NASDAQ:ATRS)

Antares Pharma (NASDAQ ATRS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/9/2017Leonard S JacobDirectorSell230,000$4.05$931,500.00View SEC Filing  
10/3/2017Thomas J GarrityDirectorSell30,000$3.50$105,000.00View SEC Filing  
6/9/2017Fred M PowellInsiderBuy130,000$2.79$362,700.00View SEC Filing  
4/5/2017Robert F AppleCEOSell40,000$3.00$120,000.00View SEC Filing  
4/4/2017Leonard S JacobDirectorSell41,762$2.89$120,692.18View SEC Filing  
4/4/2017Robert F AppleCEOSell37,000$3.00$111,000.00View SEC Filing  
4/3/2017Leonard S JacobDirectorSell20,000$2.88$57,600.00View SEC Filing  
3/31/2017Thomas J GarrityDirectorSell30,000$2.91$87,300.00View SEC Filing  
12/9/2016Fred M PowellInsiderBuy100,000$2.03$203,000.00View SEC Filing  
3/21/2016Peter J GrahamSVPBuy20,000$0.77$15,400.00View SEC Filing  
3/18/2016James E FickenscherCFOBuy135,000$0.72$97,200.00View SEC Filing  
3/18/2016Leonard S JacobDirectorBuy50,000$0.72$36,000.00View SEC Filing  
3/18/2016Robert F AppleCEOBuy60,000$0.72$43,200.00View SEC Filing  
9/30/2015James E FlynnMajor ShareholderSell249,998$1.69$422,496.62View SEC Filing  
9/29/2015James E FlynnMajor ShareholderSell225,048$1.82$409,587.36View SEC Filing  
9/28/2015James E FlynnMajor ShareholderSell1,353,483$1.81$2,449,804.23View SEC Filing  
8/24/2015Robert P Roche JrDirectorBuy5,000$1.77$8,850.00View SEC Filing  
8/13/2015Robert P Roche JrDirectorBuy5,000$1.94$9,700.00View SEC Filing  
7/20/2015James E FlynnInsiderSell231,793$2.17$502,990.81View SEC Filing  
7/8/2015James E FlynnMajor ShareholderSell444,341$2.05$910,899.05View SEC Filing  
7/7/2015James E FlynnMajor ShareholderSell198,651$2.09$415,180.59View SEC Filing  
7/6/2015James E FlynnMajor ShareholderSell191,513$2.12$406,007.56View SEC Filing  
7/1/2015James E FlynnInsiderSell713,222$2.09$1,490,633.98View SEC Filing  
6/30/2015James E FlynnMajor ShareholderSell608,691$2.08$1,266,077.28View SEC Filing  
6/29/2015James E FlynnMajor ShareholderSell60,695$2.18$132,315.10View SEC Filing  
6/26/2015James E FlynnInsiderSell756,852$2.27$1,718,054.04View SEC Filing  
6/23/2015James E FlynnInsiderSell499,895$2.39$1,194,749.05View SEC Filing  
6/18/2015James E FlynnInsiderSell478,366$2.44$1,167,213.04View SEC Filing  
6/15/2015James E FlynnInsiderSell748,030$2.44$1,825,193.20View SEC Filing  
3/23/2015Leonard S JacobDirectorSell23,500$2.68$62,980.00View SEC Filing  
9/10/2014Eamonn P HobbsCEOBuy9,000$2.20$19,800.00View SEC Filing  
8/13/2014Robert P Roche JrDirectorBuy5,000$1.96$9,800.00View SEC Filing  
8/11/2014Marvin SamsonDirectorBuy25,000$2.00$50,000.00View SEC Filing  
12/9/2013Paul WottonCEOSell64,100$4.00$256,400.00View SEC Filing  
10/14/2013Robert AppleCFOSell22,000$5.05$111,100.00View SEC Filing  
9/3/2013Anton GuethDirectorSell25,000$4.42$110,500.00View SEC Filing  
9/3/2013Paul WottonCEOSell35,000$4.41$154,350.00View SEC Filing  
8/1/2013Anton GuethDirectorSell25,000$4.41$110,250.00View SEC Filing  
8/1/2013Paul K WottonCEOSell35,000$4.42$154,700.00View SEC Filing  
7/1/2013Anton GuethDirectorSell25,000$4.15$103,750.00View SEC Filing  
7/1/2013Paul K WottonCEOSell35,000$4.14$144,900.00View SEC Filing  
6/25/2013Eamonn P HobbsDirectorSell23,500$4.19$98,465.00View SEC Filing  
6/4/2013Robert F AppleCFOSell115,000$4.02$462,300.00View SEC Filing  
6/3/2013Anton GuethDirectorSell25,000$4.01$100,250.00View SEC Filing  
6/3/2013Kaushik J DaveEVPSell48,000$4.01$192,480.00View SEC Filing  
6/3/2013Paul K WottonCEOSell125,000$4.01$501,250.00View SEC Filing  
5/31/2013Thomas J GarrityDirectorSell13,000$4.08$53,040.00View SEC Filing  
5/17/2013Leonard S JacobDirectorSell17,000$4.00$68,000.00View SEC Filing  
11/16/2012Leonard S JacobDirectorBuy10,000$3.44$34,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Antares Pharma (NASDAQ ATRS) News Headlines

Source:
DateHeadline
Antares Pharma, Inc. (ATRS) Expected to Post Earnings of -$0.03 Per ShareAntares Pharma, Inc. (ATRS) Expected to Post Earnings of -$0.03 Per Share
www.americanbankingnews.com - December 16 at 3:24 AM
Quotidian Technical Highlights on Selected Medical Supplies Stocks -- Antares ...Quotidian Technical Highlights on Selected Medical Supplies Stocks -- Antares ...
www.prnewswire.com - December 15 at 8:37 AM
IMPORTANT ANTARES PHARMA, INC. INVESTOR REMINDER – LEAD PLAINTIFF DEADLINE RAPIDLY APPROACHING: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed on behalf of investors who purchased Antares Pharma, Inc.IMPORTANT ANTARES PHARMA, INC. INVESTOR REMINDER – LEAD PLAINTIFF DEADLINE RAPIDLY APPROACHING: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed on behalf of investors who purchased Antares Pharma, Inc.
finance.yahoo.com - December 14 at 8:54 AM
ATRS EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Antares Pharma, Inc. and a Lead Plaintiff Deadline of December 22, 2017ATRS EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Antares Pharma, Inc. and a Lead Plaintiff Deadline of December 22, 2017
finance.yahoo.com - December 14 at 8:54 AM
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Antares Pharma, Inc. Shareholders of Commencement of a Class Action and a Lead Plaintiff Deadline of December 22, 2017 - ATRSEQUITY ALERT: Levi & Korsinsky, LLP Reminds Antares Pharma, Inc. Shareholders of Commencement of a Class Action and a Lead Plaintiff Deadline of December 22, 2017 - ATRS
finance.yahoo.com - December 13 at 3:27 PM
Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Antares Pharma, Inc. (ATRS) and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Antares Pharma, Inc. (ATRS) and Encourages Investors to Contact the Firm
finance.yahoo.com - December 13 at 8:49 AM
The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Antares Pharma, Inc. Shareholders and a Lead Plaintiff Deadline of December 22, 2017 (ATRS)The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Antares Pharma, Inc. Shareholders and a Lead Plaintiff Deadline of December 22, 2017 (ATRS)
finance.yahoo.com - December 13 at 8:49 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Antares Pharma, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017 - ATRSSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Antares Pharma, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017 - ATRS
finance.yahoo.com - December 9 at 9:01 AM
ATRS EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Antares Pharma, Inc. and a Lead Plaintiff Deadline of December 22, 2017ATRS EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Antares Pharma, Inc. and a Lead Plaintiff Deadline of December 22, 2017
finance.yahoo.com - December 7 at 8:49 AM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Antares Pharma, Inc. (ATRS) and Lead Plaintiff Deadline: December 22, 2017SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Antares Pharma, Inc. (ATRS) and Lead Plaintiff Deadline: December 22, 2017
finance.yahoo.com - December 6 at 3:26 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Antares Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017 - ATRSSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Antares Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017 - ATRS
finance.yahoo.com - December 6 at 9:11 AM
Scott+Scott, Attorneys at Law, LLP Reminds Investors of December 22nd Lead Plaintiff Deadline in Securities Class Action Against Antares Pharma, Inc. (ATRS)Scott+Scott, Attorneys at Law, LLP Reminds Investors of December 22nd Lead Plaintiff Deadline in Securities Class Action Against Antares Pharma, Inc. (ATRS)
finance.yahoo.com - December 5 at 3:26 PM
The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Antares Pharma, Inc. Shareholders and a Lead Plaintiff Deadline of December 22, 2017 (ATRS)The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Antares Pharma, Inc. Shareholders and a Lead Plaintiff Deadline of December 22, 2017 (ATRS)
finance.yahoo.com - December 5 at 3:26 PM
ATRS INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Antares Pharma, Inc. Investors and Encourages Investors to ...ATRS INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Antares Pharma, Inc. Investors and Encourages Investors to ...
www.businesswire.com - December 5 at 8:50 AM
ATRS INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Antares Pharma, Inc. Investors and Encourages Investors to Contact the FirmATRS INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Antares Pharma, Inc. Investors and Encourages Investors to Contact the Firm
finance.yahoo.com - December 5 at 8:50 AM
DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Antares Pharma, Inc. To Contact The FirmDEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Antares Pharma, Inc. To Contact The Firm
finance.yahoo.com - December 1 at 11:21 AM
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Antares Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017 - ATRSEQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Antares Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017 - ATRS
finance.yahoo.com - December 1 at 11:21 AM
Report: Exploring Fundamental Drivers Behind Lannett, Oclaro, Antares Pharma, Workday, The Medicines, and Celldex Therapeutics — New Horizons, Emerging Trends, and Upcoming DevelopmentsReport: Exploring Fundamental Drivers Behind Lannett, Oclaro, Antares Pharma, Workday, The Medicines, and Celldex Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - December 1 at 11:21 AM
ETFs with exposure to Antares Pharma, Inc. : November 30, 2017ETFs with exposure to Antares Pharma, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 3:26 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Antares Pharma, Inc. (ATRS) & Lead Plaintiff Deadline: December 22, 2017SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Antares Pharma, Inc. (ATRS) & Lead Plaintiff Deadline: December 22, 2017
finance.yahoo.com - November 29 at 3:25 PM
ATRS INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Antares Pharma, Inc. InvestorsATRS INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Antares Pharma, Inc. Investors
finance.yahoo.com - November 29 at 3:25 PM
$14.80 Million in Sales Expected for Antares Pharma, Inc. (ATRS) This Quarter$14.80 Million in Sales Expected for Antares Pharma, Inc. (ATRS) This Quarter
www.americanbankingnews.com - November 29 at 2:56 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Antares Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017 – ATRSINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Antares Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017 – ATRS
feeds.benzinga.com - November 29 at 2:49 AM
ATRS LOSS NOTICE: Rosen Law Firm Reminds Antares Pharma, Inc. Investors of Important Deadline in Class ActionATRS LOSS NOTICE: Rosen Law Firm Reminds Antares Pharma, Inc. Investors of Important Deadline in Class Action
finance.yahoo.com - November 28 at 3:25 PM
ATRS LOSS NOTICE: Rosen Law Firm Reminds Antares Pharma, Inc. Investors of Important Deadline in Class ActionATRS LOSS NOTICE: Rosen Law Firm Reminds Antares Pharma, Inc. Investors of Important Deadline in Class Action
finance.yahoo.com - November 28 at 3:25 PM
Reviewing Antares Pharma (ATRS) and Zimmer Biomet (ZBH)Reviewing Antares Pharma (ATRS) and Zimmer Biomet (ZBH)
www.americanbankingnews.com - November 28 at 11:16 AM
The Klein Law Firm Notifies Investors of a Class Action Filed on Behalf of Antares Pharma, Inc. Shareholders and a Lead Plaintiff Deadline of December 22, 2017 (ATRS)The Klein Law Firm Notifies Investors of a Class Action Filed on Behalf of Antares Pharma, Inc. Shareholders and a Lead Plaintiff Deadline of December 22, 2017 (ATRS)
finance.yahoo.com - November 28 at 6:11 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Antares Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017 - ATRSINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Antares Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017 - ATRS
finance.yahoo.com - November 27 at 2:36 PM
Antares Pharma, Inc. (ATRS) Receives Average Recommendation of "Buy" from BrokeragesAntares Pharma, Inc. (ATRS) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 23 at 1:52 AM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Antares Pharma, Inc. (ATRS) & Lead Plaintiff Deadline - December 22, 2017SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Antares Pharma, Inc. (ATRS) & Lead Plaintiff Deadline - December 22, 2017
finance.yahoo.com - November 22 at 4:50 PM
ATRS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Antares Pharma, Inc. and a Lead Plaintiff Deadline of December 22, 2017ATRS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Antares Pharma, Inc. and a Lead Plaintiff Deadline of December 22, 2017
finance.yahoo.com - November 22 at 4:50 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Antares Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017 - ATRSINVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Antares Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017 - ATRS
finance.yahoo.com - November 20 at 5:28 PM
Key Risk Factors Facing Antares Pharma in 2017Key Risk Factors Facing Antares Pharma in 2017
finance.yahoo.com - November 17 at 3:52 PM
The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Antares Pharma, Inc. Shareholders and a Lead Plaintiff Deadline of December 22, 2017The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Antares Pharma, Inc. Shareholders and a Lead Plaintiff Deadline of December 22, 2017
finance.yahoo.com - November 17 at 3:52 PM
Taking a Deeper Look at Antares Pharma’s Financials in 2017Taking a Deeper Look at Antares Pharma’s Financials in 2017
finance.yahoo.com - November 17 at 9:06 AM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Antares Pharma, Inc. (ATRS) & Lead Plaintiff Deadline - December 22, 2017SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Antares Pharma, Inc. (ATRS) & Lead Plaintiff Deadline - December 22, 2017
finance.yahoo.com - November 16 at 4:25 PM
Analysts’ Recommendations for Antares Pharma in November 2017Analysts’ Recommendations for Antares Pharma in November 2017
finance.yahoo.com - November 16 at 4:25 PM
IMPORTANT ANTARES PHARMA, INC. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Investors Who Purchased Antares Pharma, Inc.IMPORTANT ANTARES PHARMA, INC. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Investors Who Purchased Antares Pharma, Inc.
finance.yahoo.com - November 16 at 4:25 PM
Antares Pharma’s Focus on Self-Administered Injectable DrugsAntares Pharma’s Focus on Self-Administered Injectable Drugs
finance.yahoo.com - November 16 at 4:25 PM
ATRS INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Antares Pharma, Inc. and a Lead Plaintiff Deadline of December 22, 2017ATRS INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Antares Pharma, Inc. and a Lead Plaintiff Deadline of December 22, 2017
finance.yahoo.com - November 16 at 4:25 PM
Which Products Are Driving Revenues for Antares Pharma in 2017?Which Products Are Driving Revenues for Antares Pharma in 2017?
finance.yahoo.com - November 16 at 4:25 PM
Antares Pharma’s Sale of ZomaJet to Ferring PharmaceuticalsAntares Pharma’s Sale of ZomaJet to Ferring Pharmaceuticals
finance.yahoo.com - November 16 at 11:33 AM
Antares Pharma On Sale - Seeking AlphaAntares Pharma On Sale - Seeking Alpha
seekingalpha.com - November 15 at 1:47 AM
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Antares Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Antares Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017
finance.yahoo.com - November 14 at 4:41 PM
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Antares Pharma, Inc. (Nasdaq:ATRS) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action LawsuitINVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Antares Pharma, Inc. (Nasdaq:ATRS) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
feeds.benzinga.com - November 13 at 11:47 AM
Antares Pharma, Inc. (ATRS) Expected to Post FY2017 Earnings of ($0.12) Per ShareAntares Pharma, Inc. (ATRS) Expected to Post FY2017 Earnings of ($0.12) Per Share
www.americanbankingnews.com - November 13 at 3:58 AM
Antares Pharma, Inc. (ATRS) Sees Significant Drop in Short InterestAntares Pharma, Inc. (ATRS) Sees Significant Drop in Short Interest
www.americanbankingnews.com - November 12 at 1:32 AM
EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Antares Pharma, Inc. - ATRSEQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Antares Pharma, Inc. - ATRS
www.thestreet.com - November 11 at 4:00 PM
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Antares Pharma, Inc. – ATRSEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Antares Pharma, Inc. – ATRS
finance.yahoo.com - November 11 at 4:00 PM
SHAREHOLDER ALERT:  Pomerantz Law Reminds Shareholders with Losses on their Investment in Antares Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline – ATRSSHAREHOLDER ALERT:  Pomerantz Law Reminds Shareholders with Losses on their Investment in Antares Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline – ATRS
finance.yahoo.com - November 11 at 9:48 AM

SEC Filings

Antares Pharma (NASDAQ:ATRS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Antares Pharma (NASDAQ:ATRS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Antares Pharma (NASDAQ ATRS) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.